Click to launch & play an online audio visual presentation by Prof. Helen McShane on Global progress in TB vaccine development, part of a collection of multimedia lectures.
Given that BCG is currently the only licensed vaccine against human TB, it is likely that any new vaccine or vaccination strategy will be based around BCG. In this review we discuss immune responses elicited by mycobacteria in cattle and the novel approaches emerging for the control of bovine ...
Achieving TB elimination requires a direct attack on the reservoir of latent infection, with a drug or a vaccine (or both) that is effective against established infection. For instance, if just 8% of people infected with M. tuberculosis are fully and permanently protected each year, incidence ...
In a recent study, researchers from the USA and Europe have found a new vaccine strategy that produces stronger, longer-lasting protection from TB infection than the currently used bacille Calmette-Guerin (BCG) vaccine. Tuberculosis is caused by the bacterium Mycobacterium tuberculosis and was ...
The new rotavirus vaccines RV5 and RV1 have been associated with small increase in intussusception risk in active vaccine surveillance studies. It is uncle... Despina,G,Contopoulos-Ioannidis,... - 《Pediatric Infectious Disease Journal》 被引量: 4发表: 2015年 Practice Patterns and Outcomes Assoc...
The only licensed tuberculosis (TB) vaccine, Bacillus Calmette Guerin (BCG), fails to reliably protect adolescents and adults from pulmonary TB, resulting in ~1.6 million deaths annually. Protein subunit vaccines have shown promise against TB in clinical studies. Unfortunately, most subunit vaccines ...
Serum samples were collected by the South African Tuberculosis Vaccine Initiative (SATVI) and the Desmond Tutu HIV Centre at the Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, according to standard protocols [27] and cryopreserved at -80°C. For this retrospective...
tuberculosis complex genome, which is absent from the BCG vaccine. Although IGRAs have desirable performance characteristics such as higher specificity, they are more costly than TST and require appropriate laboratory infrastructure and highly specialized training. The WHO currently endorses QuantiFERON (...
At an international gathering of TB vaccine researchers in Tallinn today, the Aeras Global TB Vaccine Foundation announced it will initiate a clinical trial of an investigational live recombinant tuberculosis vaccine to be led by researchers at Saint Louis University in St. Louis, Missouri, USA. The...
really want to make the final push toward TB elimination, we will have to understand the TB epidemic as a health equity issue," Humayun said. "The low statewide aggregated estimates are misleading as they mask the underlying disparities that potentially fuel the remaining TB epidemic in Arkansas...